GynecologyGynecology2079-56962079-5831Consilium Medicum28531Research ArticleUterine fibroids and fertilityKuznetsovaI Vms.smith.ivk@gmail.comEvsyukovaL V-I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian FederationI.P.Pavlov Ryazan State Medical University of the Ministry of Health of the Russian Federation15062016183232909042020Copyright © 2016, Consilium Medicum2016Despite the fact that the study of uterine fibroids has been widely discussed, the problem still remains unsolved. Uterine fibroids are the most common benign neoplasm of female genital system. Increasingly diagnosed in recent decades, uterine fibroids in women planning a pregnancy, which is associated primarily with the social factor: modern women tend to postpone the time of childbirth until a stable material and social status, which often occurs close to the late reproductive age, when the prevalence of uterine fibroids naturally increases. The link between uterine fibroids and fertility disorders ambiguous, but, without a doubt, the presence of uterine fibroids should be taken into account in women with infertility and habitual miscarriage. The optimal solution, but today, in addition to surgical treatment task of restoring fertility in women with uterine fibroids do not exist, there is a possibility of conservative management of these patients. Advantages and disadvantages of surgical and conservative tactics restore fertility in patients with uterine myoma should undergo evaluation and further development.uterine fibroidsfertilityinfertilityrecurrent spontaneous miscarriagepregnancy planningmyomectomyulipristal acetateмиома маткифертильностьбесплодиепривычный самопроизвольный выкидышпланирование беременностимиомэктомияулипристала ацетат[Миома матки: диагностика, лечение и реабилитация (клинические рекомендации по ведению больных). Под ред. Л.В.Адамян. М.: 2014.][Marret H, Fritel X, Ouldamer L et al. Therapeutic management of uterine fibroid tumors: updated French guidelines. Eur J Obstet Gynecol Reprod Biol 2012; 165: 156-64.][Parker W.H. Etiology, symptomatology and diagnosis of uterine myoma. Fertil Steril 2007; 87: 726-36.][Giraudet G, Lucot J.P et al. Except fertility, place of myomectomy in perimenopause and after menopause. Gynecol Obstet Biol Reprod 2011; 40 (8): 902-17.][Gupta S, Jose J, Manyonda I. Clinical presentation of fibroids. Best Pract Res Clin Obstet Gynaecol 2008; 22: 615-26.][Levy B.S. Management of uterine fibroids. Acta Obstet Gynecol Scand 2008; 87 (8): 812-23. Practice Committee of American Society for Reproductive Medicine in collaboration with Society of Reproductive Surgeons. Myomas and reproductive function. Fertil Steril 2008; 90 (Suppl. 5): S125-130.][Somigliana E, Vercellini P, Daguati R et al. Fibroids and female reproduction: a critical analysis of the evidence. Hum Reprod Update 2007; 13: 465-76.][Волков В.Г., Гусева Н.В., Горшкова И.А. Оптимизация консервативного лечения миомы матки антипрогестеронами и оценка влияния проводимой терапии на качество жизни женщин. Вестн. новых мед. технологий. 2011; 18 (1): 92.][Duhan N. Current and emerging treatments for uterine myoma an update. Int J Womens Health 2011; 3: 231-41.][Sozen I, Arici A. Cellular biology of myomas: interaction of sex steroids with cytokines and growth factors. Obstet Gynecol Clin NA 2006; 33 (1): 41-58.][Chen B, Wen Y, Yu X.Y, Polan M.L. Relaxin increases elastase activity and protease inhibitors in smooth muscle cells from tye myometrium compared with cells from leiomyomas. Fertil Steril 2009; 91 (4): 1351-4.][Georgieva B, Milev I, Minkov I et al. Charactrisation of the uterine leiomyoma microRNAome by deep sequencing. Genomics 2012; 99: 275-81.][Makinen N, Mehine M, Tolvanen J et al. MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science 2011; 334: 252-9.][Vegan K. MED12 mutations and uterine fibrinoids. Nature Genetics 2011; 43: 928-31.][Pritts E.A, Parker W.H, Olive D.L. Fibroids and infertility: an update systematic review of the evidence. Fertil Steril 2009; 91 (4): 1215-23.][Indman P.D. Hysteroscopic treatment of submucous fibroids. Clin Obstet Gynecol 2006; 49: 811-20.][Kolankaya A, Arici A. Myomas and assisted reproductive technologies: when and how to act? Obstet Gynecol Clin North Am 2006; 33: 145-52.][Klatsky P.C, Tran N.D, Caughey A.B, Fujimoto V.Y. Fibroids and reproductive outcomes: a systematic literature review from conception to delivery. Am J Obstet Gynecol 2008; 198: 357-66.][Chalazonitis A, Tzovara I, Laspas F et al. Hysterosalpingography: technique and applications. Curr Probl Diagn Radiol 2009; 38 (5): 199-205.][Dixon D, Parrott E.C, Segars J.H et al. The second National Institutes of Health International Congress on advances in uterine leiomyoma research: conference summary and future recommendations. Fertil Steril 2006; 86: 800-6.][Polena V, Merqui J.L, Perrot N et al. Long - term results of hysteroscopic myomectomy in 235 patients. Eur J Obstet Gynecol Reprod Biol 2007; 130: 232-7.][Di Spezio Sardo A, Mazzon I, Bramante S et al. Hysteroscopic myomectomy: a comprehensive review of surgical techniques. Hum Reprod Update 2008; 14: 10-9.][Петракова С.А., Буянова С.Н., Мгелиашвили М.В. Возможности миомэктомии в коррекции репродуктивного здоровья женщин с миомой матки. Рос. вестн. акушера - гинеколога. 2009; 1: 30-5.][Кулинич С.И., Бурлакова О.А. Предгравидарная подготовка женщин репродуктивного возраста и профилактика рецидива миомы матки в послеоперационном периоде после миомэктомии. Сиб. мед. журн. 2011; 6: 119-22.][Meng X, He G, Zhang J. A comparative study of fibroid ablation rates using radio frequency and high - intensity focused ultrasound. Cvir 2010; 33: 794-9.][Toor S.S, Tan K.T, Simons M.E. Clinical Failure after Uterine Artery Embolization: Evaluation of Patient and MR Imaging Characteristics. J Vasc Int Radiol 2008; 19: 662-7.][Scheurig C, Gauruder-Burmester A, Kluner C. Uterine artery embolization for symptomatic fibroids: short - term versus mid - term changes in disease - specific symptoms, quality of life and magnetic resonance imaging results. Hum Reprod 2006; 21: 3270-7.][Smeets A.J, Nijenhuis R.J, Jan van Rooij W. Embolization of Uterine Leiomyomas with Polyzene F-coated Hydrogel Microspheres: Initial Experience. J Vasc Intervent Radiol 2010; 21: 1830-4.][Horhoianu I.A, Horhoianu V.V, Joita D, Carstoiu M, Dorobat B. Uterine artery embolization for leioyomas, ultrasonography and angiography aspects. J Med Life 2012; 5 (4): 491-5.][Naguib N.N.N, Mbalisike E, Nour-Eldin N.E.A. Leiomyoma Volume Changes at Follow - up after Uterine Artery Embolization: Correlation with the Initial Leiomyoma Volume and Location. J Vasc Intervent Radiol 2010; 21: 490-5.][Scheurig-Muenkler C, Koesters C, Grieser C. Treatment failure after uterine artery embolization: Prospective cohort study with multifactorial analysis of possible predictors of long - term outcome. Eur J Radiol 2012; 81: 727-31.][Kim H.S, Tsai J, Patra A. Effects of Utero - ovarian Anastomoses on Clinical Outcomes and Repeat Intervention Rates after Uterine Artery Embolization. J Vasc Intervent Radiol 2006; 17: 783-9.][Smeets A.J, Nijenhuis R.J, Boekkooi P.F. Safety and Effectiveness of Uterine Artery Embolization in Patients with Pedunculated Fibroids. J Vasc Intervent Radiol 2009; 20: 1172-5.][Firouznia K, Ghanaati H, Sanaati M et al. Pregnancy after uterine artery embolization for symptomatic fibroids: a series of 15 pregnancies. AJR Am J Roentgenol 2009; 192 (6): 1588-92.][Mara M, Maskova J, Fucikova Z et al. Midterm clinical and first reproductive results of a randomized controlled trial comparing uterine fibroid embolization and myomectomy. Cardiovasc Intervent Radiol 2008; 31 (1): 73-85.][Hovsepian D.M, Ratts V.S, Rodriguez M et al. A prospective comparison of the impact of uterine artery embolization, myomectomy, and hysterectomy on ovarian function. J Vasc Interv Radiol 2006; 17 (7): 1111-5.][Hehenkamp W.J.K, Volkers N.A, Broekmans F.J.M et al. Loss of ovarian reserve after uterine artery embolization: a randomized comparison with hysterectomy. Hum Reprod 2007; 22 (7): 1996-2005.][Yin P, Lin Z, Reierstad S et al. Transcription factor KLF11 integrates progesterone receptor signaling and proliferation in uterine leiomyoma cells. Cancer Res 2010; 70 (4): 1722-30.][Kim J.J, Sefton E.C. The role of progesterone signaling in the pathogenesis of uterine leiomyoma. Mol Cell Endocrinol 2012; 35(2): 223-31.][Donnez J, Tomaszewski J, Vázquez F et al.; PEARL II Study Group. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med 2012; 366 (5): 421-32.][Islam M.S, Protic O, Giannubilo S.R et al. Uterine leiomyoma: available medical treatments and new possible therapeutic options. J Clin Endocrinol Metab 2013; 98: 921-34.][Spitz A.M. Clinical utility of progesterone receptor modulators and their effect on the endometrium. Curr Opin Obtet Gynecol 2009; 21: 318-24.][Maruo T. Translation research in women’s health: From bedside to bench and from bench to bedside. Int J Gynecol Obstet 2010; 109: 83-3.][Xu Q, Ohara N, Liu J et al. Progesterone receptor modulator CDB2914 induces extracellular matrix metalloproteinase inducer in cultured human uterine leiomyoma cells. Mol Hum Reprod 2008; 14: 181-91.][Yoshida S, Ohara N, Xu Q et al. Cell - type specific actions of progesterone receptor modulators in regulation of uterine leiomyoma growth. Semin Reprod Med 2010; 28: 260-73.][Donnez J, Tatarchuk T.F, Bouchard P et al. PEARL I Study Group. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med 2012; 366: 409-20.][Donnez J, Vazquez F, Tomaszewski J et al. Long - term treatment of uterine fibroids with ulipristal acetate. Fertil Steril 2014; 101: 1565-73.][Donnez J, Hudecek R, Donnez O et al. Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids. Fertil Steril 2015; 103: 519-27.][Mutter G.L, Bergeron C, Deligdisch L et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol 2008; 21 (5): 591-98.][Williams A.R, Bergeron C, Barlow D.H, Ferenczy A. Endometrial morphology after treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate. Int J Gynecol Pathol 2012; 31: 556-69.][Chabbert-Buffet N, Pintiaux-Kairis A, Bouchard P. Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic -pituitary - ovarian axis and endometrium in normal women: a prospective, randomized, placebo - controlled trial. J Clin Endocrinol Metab 2007; 92 (9): 3582-9.][Luyckx M, Squifflet J.L, Jadoul P et al. First series of 18 pregnancies after ulipristal acetate treatment for uterine fibroids. Fertil Steril 2014; 102 (5): 1404-9.]